Augmenix, a Waltham, MA-based maker of hydrogel implants for reducing the side effects of radiation therapy, has raised $3 million in an equity and debt financing round, according to an SEC filing. The filing does not list the investors. Some of the firm’s previous backers include Catalyst Health Ventures, Pinnacle Ventures, and Versant Ventures. Last year the firm revealed that its SpaceOAR System, which has gained commercial clearance in Europe, was used in a radiation procedure in Germany.
Author: Ryan McBride
Ryan is an award-winning business journalist who contributes to our life sciences and technology coverage. He was previously a staff writer for Mass High Tech, a Boston business and technology newspaper, where he and his colleagues won a national business journalism award from the Society of American Business Editors and Writers in 2008. In recent years, he has made regular TV appearances on New England Cable News.
Prior to MHT, Ryan covered the life sciences, technology, and energy sectors for Providence Business News. He graduated with honors from the University of Rhode Island in 2001 with a bachelor’s degree in communications. When he’s not chasing down news, Ryan enjoys mountain biking and skiing in his home state of Vermont.
View all posts by Ryan McBride
